Principal Investigator
David Baidal
Enrollment Status
Closed
Clinical Trial ID
Institutional Protocol #
20230487
Clinical Trial Summary
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Diamyd to Preserve Endogenous Beta Cell Function in Adolescents and Adults with Recently Diagnosed Type 1 Diabetes, Carrying the Genetic HLA DR3-DQ2 Haplotype
Phase
TBD
Funding Agency/Sponsor
Industry
Disease
Other
Contact Information
Study Contact
Burlett Masters
Phone Number
+1 (305) 2435354
Email
bmasters2@miami.edu